<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2434">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05256251</url>
  </required_header>
  <id_info>
    <org_study_id>20211015ZJS001</org_study_id>
    <nct_id>NCT05256251</nct_id>
  </id_info>
  <brief_title>Westlake Longevity Cohort</brief_title>
  <acronym>We-Longevity</acronym>
  <official_title>Westlake Longevity Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Westlake University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Sixth Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Westlake University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among&#xD;
      centenarians, nonagenarians, senior citizens and their family members up to three generations&#xD;
      living in Lishui, China. The primary aim of this cohort is to characterize the multi-omics&#xD;
      molecular characteristics of healthy longevity and their dynamic trajectories. Another aim of&#xD;
      We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics&#xD;
      molecular characteristics of healthy longevity, and to facilitate the development of&#xD;
      personalized nutritional/lifestyle recommendation for the public.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aging is a major risk factor for most fatal diseases, such as Alzheimer's disease, type 2&#xD;
      diabetes, cardiovascular disease and cancer. Global population aging is becoming increasingly&#xD;
      serious, and this trend is mainly driving the annual increase in the prevalence of&#xD;
      aging-related diseases. Healthy longevity are influenced by a variety of factors, such as&#xD;
      diet structure, lifestyle, ecological environment, gut microbiome and genetics. At present,&#xD;
      the researches on healthy longevity are mainly focused on Drosophila, nematodes and mouse&#xD;
      models, and few studies on longevity population. Centenarians and nonagenarians are the best&#xD;
      objects to study healthy longevity. However, the multi-omics molecular characteristics and&#xD;
      regulatory mechanism of healthy longevity in human are still unclear. There, the present&#xD;
      We-Longevity design includes 200 centenarians, 600 nonagenarians, 400 senior citizens and&#xD;
      1200 family members up to three generations. We will determine the fecal/serum metabolome,&#xD;
      gut microbiome serum proteome and genome, together with diet, lifestyle and disease&#xD;
      information. We will then follow up the centenarians every six months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2021</start_date>
  <completion_date type="Anticipated">November 14, 2031</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>aging</measure>
    <time_frame>36 months</time_frame>
    <description>Physical frailty will be evaluated by using Fried's criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>36 months</time_frame>
    <description>Fecal microbiome will be analyzed by 16S rRNA gene sequencing and metagenome sequencing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolomics of serum and gut microbiome</measure>
    <time_frame>36 months</time_frame>
    <description>Metabolomics of serum and gut microbiome will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proteomic profiling of serum</measure>
    <time_frame>36 months</time_frame>
    <description>Proteomic characterization of serum will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genome</measure>
    <time_frame>36 months</time_frame>
    <description>Genomic characterization will be analyzed by Illumina ASA-750K arrays.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>36 months</time_frame>
    <description>Cognitive function will be evaluated by using Mini-Mental State Examination (MMSE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose examination of blood samples</measure>
    <time_frame>36 months</time_frame>
    <description>Blood glucose will be analyzed by automatic biochemical analyser.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood blood lipids examination of blood samples</measure>
    <time_frame>36 months</time_frame>
    <description>Blood blood lipids (HDL, LDL, TC and TG) will be analyzed by automatic biochemical analyser.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokines examination of blood samples</measure>
    <time_frame>36 months</time_frame>
    <description>Serum cytokines (IFNγ, IL10, IL12p70, IL13, IL1β, IL2, IL4, IL6, IL8 and TNFα) will be analyzed by electrochemiluminescence immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neurotranszmitters examination of blood samples</measure>
    <time_frame>36 months</time_frame>
    <description>Serum neurotranszmitters (dopamine, choline, acetyl choline, tyramine, tryptamine, 5-hydroxyindoleacetic acid, phenylpyruvic acid, 3,4-dihydroxyphenylacetic acid and 3-hydroxyo-aminobenzoic acid) will be analyzed by liquid chromatograph-mass spectrometer (LC/MS).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Aging</condition>
  <condition>Alzheimer's Disease</condition>
  <condition>Neurodegenerative Diseases</condition>
  <condition>Cardiometabolic Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All the participants should be Chinese residents, regardless of the ethics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants aged 50 years or order.&#xD;
&#xD;
          -  Participants live in Lishui, China.&#xD;
&#xD;
          -  Participants intend to remain in Lishui for ≥3 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with cancer, serious medical disorders or infectious diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ju-Sheng Zheng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westlake University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ju-Sheng Zheng, PhD</last_name>
    <phone>86-0571-86915303</phone>
    <email>zhengjusheng@westlake.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zengliang Jiang, PhD</last_name>
    <phone>86-0571-86915303</phone>
    <email>jiangzengliang@westlake.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lishui City People's Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ju-Sheng Zheng, PhD</last_name>
      <phone>86-0571-86915303</phone>
      <email>zhengjusheng@westlake.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zengliang Jiang, PhD</last_name>
      <phone>86-0571-86915303</phone>
      <email>jiangzengliang@westlake.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ju-Sheng Zheng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 21, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2022</study_first_posted>
  <last_update_submitted>June 13, 2022</last_update_submitted>
  <last_update_submitted_qc>June 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

